Latest Funding Opportunities

This is a curated list of funding opportunities for Cancer Center members.

Extramural Funding Opportunities

AHEAD (Advancing Head and Neck Cancer Early Detection Research (U01 Clinical Trial Not Allowed)

Sponsor: National Institutes of Health (NIH); National Institute of Dental and Craniofacial Research (NIDCR); National Cancer Institute (NCI)

Abstract: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that focus on early detection of HNC by applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions, and identifying prognostic signatures on the transformation from premalignant to malignant lesions. Better understanding of the molecular characteristics of dysplastic lesions and early recurrence are needed for improving lesion classification relevant to predicting cancer progression, which could have a significant impact on cancer prevention and treatment optimization.

Application Due Date: March 14, 2023

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kinds First Pediatric Research Program (X01 Clinical Trial Not Allowed)

Sponsor: National Institutes of Health (NIH)

Abstract: As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer or structural birth defect cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of structural birth defects, to study the molecular basis of the associations between birth defects and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing Kids First Program projects. These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community.

Application Due Date: March 22, 2023

DoD Breast Cancer, Clinical Research Extension Award

Sponsor: Office of Congressionally Directed Medical Research Programs (CDMRP); U.S. Army Medical Research and Material Command (USAMRMC); Department of the Army; United States Department of Defense (DOD)

Abstract: The FY23 BCRP Clinical Research Extension Award aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.

Pre-Application Due Date: March 28, 2023

Application Due Date: April 11, 2023

DoD Ovarian Cancer, Investigator-Initiated Research Award

Sponsor: Office of Congressionally Directed Medical Research Programs (CDMRP); U.S. Army Medical Research and Material Command (USAMRMC); Department of the Army; United States Department of Defense (DOD)

Abstract: The OCRP Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. These data may be unpublished or from the published literature.

Pre-Application Due Date: April 17, 2023

Application Due Date: July 21, 2023

AACR-AstraZeneca Career Development Award for Physicia-Scientists, in Honor of José Baselga

Sponsor: American Association for Cancer Research (AACR)

Abstract: This award has been established to honor the life and legacy of Dr. José Baselga, who was a scientific leader and supportive mentor to an entire generation of physician-scientists. Dr. Baselga’s research focused on novel molecular targeted therapeutics and he played a leading role in the clinical development of multiple cancer drugs. The intent of this program is to encourage and support early-career physician-scientists to conduct research and bolster the development of innovative targeted therapeutics. The proposed projects may be translational or clinical in nature and focused on all aspects of oncology.

LOI Due Date: February 28, 2023

Application Due Date: May 31, 2023

Robert A Winn Diversity in Clinical Trials Award Program

Sponsor: Established by the Bristol Myers Squibb Foundation

Abstract: The goal of the Robert A. Winn Career Development Award (Winn CDA) is to increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations. The program collaborates with communities to facilitate an approach to clinical and translational research that is community-informed, designed, and conducted. It provides emerging investigators the sponsorship, support, and tools they need to conduct clinical trials that will yield new treatments effective in all populations.

Application Due Date: May 12, 2023

Research Fellow Award Program

Sponsor: Multiple Myeloma Research Foundation

Abstract: The goal of this initiative is to engage and support early career investigators interested in basic and clinical research focused on multiple myeloma and its precursor conditions, with the goal of advancing our understanding of myeloma disease biology, disease risk, and treatment response and relapse.

Application Due Date: June 24, 2023

Career Catalyst Research Grant

Sponsor: Susan G Komen

Abstract:  Susan G Komen invites applications for its career catalyst research grants. These provide critical funding to support the next generation of key leaders in the quest to end breast cancer. This grant mechanism supports outstanding research focused on two important aspects of precision medicine: the development of next generation targeted therapies and the development of interventions to eliminate breast cancer health disparities. Komen requests letters of intent for research projects that address one of the following focus areas: beyond PARP inhibitors: Next generation breast cancer therapies targeting the genome and epigenome; beyond T-Cells: Next generation breast cancer immunotherapy; closing the Gap: New, approaches to address multi-level contributors to breast cancer disparities.

LOI Due Date: July 15, 2023

Application Due Date: October 5, 2023

Notices of Special Interests

Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology

Sponsor: National Cancer Institute (NCI)

Abstract: The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.

Application Due Dates: May 8, 2023; March 15, 2024; September 8, 2025

Translate »